Mylan Inc. has launched eszopiclone tablets 1 mg, 2 mg and 3 mg, the generic version of Sunovion Pharmaceuticals Inc.’s Lunesta^®.

Mylan received final FDA approval for its abbreviated new drug application (ANDA) for this product, which is indicated for the treatment of insomnia.
 

Eszopiclone tablets 1 mg, 2 mg, 3 mg had US sales of approximately $851.8 million for the 12 months ending Dec. 31, 2013, according to IMS Health, as reported by Mylan in a press statement.

Source: Mylan Inc.